IMD and Lombard Odier Recognize Ayala Corporation for its Excellence, Integrity and Contribution to Nation Building
PR Newswire - Fri Oct 17, 1:30AM CDT
Ayala Corporation, one of the oldest and largest business groups in the Philippines, was awarded the 19th annual IMD-Lombard Odier Global Family Business Award at the 25th Summit of the Family Business Network International in Dubai.
MRK: 53.43 (-1.30)
Can health-care stock funds stay on top?
By STAN CHOE - AP - Thu Oct 16, 1:54PM CDT
NEW YORK (AP) — When swings in the stock market cause anxiety to spike, like it is now, many investors aim to get healthy.
JNJ: 96.78 (-1.43), MRK: 53.43 (-1.30), PFE: 27.70 (-0.49)
BIO-Europe(R) 2014 Program is Abundant Showcase of Life Science Pharma Executives and Thought Leaders
Business Wire - Thu Oct 16, 5:00AM CDT
BIO-Europe(R) 2014 international partnering conference will take place November 3-5 in Frankfurt, Germany, at the Portalhaus Messe Frankfurt conference center. BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry. The conference annually attracts leading dealmakers from biotech, pharma and finance along with the most exciting emerging companies.
MRK: 53.43 (-1.30)
3 Small-Cap Biotech Stocks to Buy if the Market Crashes
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 15, 1:38PM CDT
The Russell 2000 small-cap stock index is the most widely used proxy for small-cap stocks and the exchange traded fund that tracks that index has tumbled 11.6% this year. That's a frightening drop, but it's been proven time and time again that...
JNJ: 96.78 (-1.43), INSY: 38.38 (+1.10), PTLA: 25.90 (+0.08), PFE: 27.70 (-0.49), MRK: 53.43 (-1.30), OPHT: 40.51 (-0.24), IWM: 107.80 (+1.20), BMY: 49.22 (+0.26), REGN: 340.71 (+5.96)
Cramer: The Bear’s on the Move -- and the Panic Is Palpable
at The Street - Wed Oct 15, 12:20PM CDT
After a prolonged period when it seemed that every dip was worth buying, we have run into a dip that isn't.
EMES: 86.20 (+10.25), MRK: 53.43 (-1.30), LINE: 24.10 (+1.70), GIS: 48.86 (-0.25)
Next Support Level for Merck (MRK) is $55.12
Comtex SmarTrend(R) - Wed Oct 15, 8:59AM CDT
Merck (NYSE:MRK) has opened bearishly below the pivot of $56.34 today and has reached the first level of support at $55.72. Should the shares continue to fall, the support pivots of $55.12 and $53.90 will be of interest.
MRK: 53.43 (-1.30)
Johnson & Johnson and Bristol-Myers Squibb’s New Collaboration Just the Tip of the Iceberg
Brian Orelli, The Motley Fool - Motley Fool - Wed Oct 15, 7:45AM CDT
If one drug is good, two drugs must be better. That seems to be what Johnson & Johnson and Bristol-Myers Squibb are thinking with the clinical trial collaboration agreement they entered to test Johnson & Johnson's Imbruvica with...
JNJ: 96.78 (-1.43), PCYC: 109.14 (+1.11), PFE: 27.70 (-0.49), MRK: 53.43 (-1.30), BMY: 49.22 (+0.26), NVS: 85.02 (-1.20)
Merck Announces Final Results of Tender Offers for Eight Series of Notes
Business Wire - Wed Oct 15, 7:02AM CDT
Merck & Co., Inc. ("Merck"
MRK: 53.43 (-1.30)
Ex-financial analyst facing insider trading charge
AP - Tue Oct 14, 6:28PM CDT
NEW YORK (AP) — A former senior finance analyst at Merck & Co. is facing an insider trading charge after authorities said Tuesday that he passed secrets to a friend he met at college that earned $722,000 in illegal profits.
MRK: 53.43 (-1.30)
Merck Announces Pricing of Tender Offers for Eight Series of Notes
Business Wire - Tue Oct 14, 5:20PM CDT
Merck & Co., Inc. ("Merck"
MRK: 53.43 (-1.30)
Can Dividend Stock GlaxoSmithKline plc Bounce Back?
George Budwell, The Motley Fool - Motley Fool - Tue Oct 14, 12:09PM CDT
The pharmaceutical industry has a bad rep when it comes to corruption in general and bribery in particular. For example, French drugmaker Sanofi recently fessed up to U.S. authorities about an illegal payment scheme to doctors in East Africa and...
PFE: 27.70 (-0.49), MRK: 53.43 (-1.30), AMGN: 130.45 (-0.45), LLY: 61.90 (-0.97), GSK: 42.88 (-0.25), BMY: 49.22 (+0.26), SNY: 50.64 (-0.86), NVS: 85.02 (-1.20)
Research and Markets: Merck's Singulair (Asthma) CysLT1 Receptor Inhibitor - Forecast and Market Analysis to 2023
Business Wire - Tue Oct 14, 8:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jlpjgt/singulair) has announced the addition of the "Singulair (Asthma) - Forecast and Market Analysis to 2023" report to their offering.
MRK: 53.43 (-1.30)
Merck's Singulair (Asthma) CysLT1 Receptor Inhibitor - Forecast and Market Analysis to 2023
M2 - Tue Oct 14, 8:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nm4qzb/singulair) has announced the addition of the "Singulair (Asthma) - Forecast and Market Analysis to 2023" report to their offering. Singulair, developed by Merck, is a CysLT1 receptor inhibitor, blocking the physiologic actions of leukotriene D4 (LTD4). LTD4 belongs to the family of Cys-LTs, which are mediators released from a variety of cells, including mast cells and eosinophils, and which bind to the family of CysLT receptors. Several studies have determined that there are higher concentrations of Cys-LTs in the airways and urine of asthmatics compared with non-asthmatic individuals. The production of CysLTs is increased in asthmatics, particularly during the early phase of bronchoconstriction that follows allergen challenge. Cys-LT signaling results in airway edema, smooth muscle contraction, and aberrant immune cell activity. Scope - Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Singulair including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Singulair for the top eight countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Singulair (montelukast) 7 Appendix For more information visit http://www.researchandmarkets.com/research/nm4qzb/singulair
MRK: 53.43 (-1.30)
Research and Markets: Merck's Dulera Asthma Treatment - Forecast and Market Analysis to 2023
Business Wire - Tue Oct 14, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xpl55r/dulera_asthma) has announced the addition of the "Dulera (Asthma) - Forecast and Market Analysis to 2023" report to their offering.
MRK: 53.43 (-1.30)
Merck's Dulera Asthma Treatment - Forecast and Market Analysis to 2023
M2 - Tue Oct 14, 6:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g2ks3p/dulera_asthma) has announced the addition of the "Dulera (Asthma) - Forecast and Market Analysis to 2023" report to their offering. Merck's Dulera is an FDC of formoterol fumarate and mometasone furoate. Mometasone furoate is a corticosteroid with potent anti-inflammatory activity. Although the precise action of corticosteroids in asthma is still unknown, their role in treating inflammation is a result of their inhibitory effects on multiple cell types and mediators involved in the asthmatic response. Mometasone furoate binds to the human glucocorticoid receptor 12 times more strongly than dexamethasone, and five times more strongly than budesonide, although how these differences in receptor affinity affect the clinical outcomes of the drug are unknown. Scope - Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Dulera including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Dulera for the top one country from 2013 to 2023. - Sales information covered for the US Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Dulera (mometasone furoate/formoterol fumarate) 7 Appendix For more information visit http://www.researchandmarkets.com/research/g2...era_asthma
MRK: 53.43 (-1.30)
Western Blotting Market Outlook 2018: Product (Instruments (Manual/Semi-automated/Automated) & Consumables (Kits/Reagents/Membrane) Analysis
M2 - Tue Oct 14, 4:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zb8c2b/western_blotting) has announced the addition of the "Western Blotting Market by Product, Consumables, by Application - End-User Analysis & Global Forecast to 2018" report to their offering. The global market was valued at $296 million in 2013 and is expected to grow at a CAGR of 4.8% from 2013 to 2018, to reach $374.2 million by 2018. The market is dominated by North America, followed by Europe, Asia, and the Rest of the World (RoW) Western Blotting Market by Product (Instruments (Manual/Semi-automated/Automated), Consumables (Kits/Reagents/Membrane), by Application (Disease Diagnosis/Agriculture/Biomedical Research) - End-User Analysis & Global Forecast to 2018 Over the years, the western blotting market, comprising of instruments and consumables, has witnessed various technological advancements to improve the sensitivity, reproducibility, quantifiability, and speed of western blot experiments. These advancements have led to a growth in the number of applications. Western blotting instruments and consumables have its applications in disease diagnosis, agriculture, biomedical and biochemical research, biologics (therapeutics), and QC tests in the biopharmaceutical industry. Western blotting consumables have the largest share in the global western blotting market, as they have a variety of applications in all areas, which include disease diagnosis, agriculture, biomedical and biochemical research, and QC tests in the biopharmaceutical, pharmaceutical, and biotechnology industry. The biomedical and biochemical research segment accounted for the largest share of the western blotting application market, as western blotting techniques are extensively used in the area to separate, purify, and detect proteins. In the coming years, the western blotting market is expected to experience the highest growth in the Asian region, with emphasis on India and China. These countries are expected to serve as new revenue pockets for the western blotting manufacturers. The high growth in these regions can be attributed to the extensive research in the field of crop science and growing pharmaceutical and biotechnology industry in India and China. In addition, rising incidences of HIV infection in the Asian region is likely to propel the market. The U.S. and European markets are witnessing increased funding for researches that use western blotting. The major players in the global western blotting market include: - Thermo Fisher Scientific, Inc. - Bio-Rad Laboratories, Inc. - GE Healthcare - Merck Millipore - Sigma-Aldrich Corporation - PerkinElmer, Inc. - Roche Applied Science - ProteinSimple, Inc. - LI-COR Biosciences - Advansta, Inc. For more information visit http://www.researchandmarkets.com/research/zb...n_blotting
SIAL: 134.40 (-0.75), MRK: 53.43 (-1.30), PKI: 40.07 (+0.22)
North America Pharmaceutical Packaging Market - By Primary Packaging Material, Type Of Packaging, Geography And Vendors - Forecasts, Trends And Shares (2014- 2019)
PR Newswire - Mon Oct 13, 5:21PM CDT
North America is a huge market for pharmaceutical companies. In 2012, North America accounted for more than 40% of the world pharmaceutical sales. Many of the giants of the pharmaceutical industry are based out of US like Pfizer, Johnson and Johnson, Merck and Co. etc.
MRK: 53.43 (-1.30)
Merck Set to Possibly Rebound After Yesterday's Selloff of 4.30%
Comtex SmarTrend(R) - Mon Oct 13, 3:54PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $55.98 to a high of $58.55. Yesterday, the shares fell 4.3%, which took the trading range below the 3-day low of $58.57 on volume of 14.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 53.43 (-1.30)
SmarTrend Watching for Potential Rebound in Shares of Merck After 4.30% Loss
Comtex SmarTrend(R) - Mon Oct 13, 3:53PM CDT
Merck (NYSE:MRK) traded in a range yesterday that spanned from a low of $55.98 to a high of $58.55. Yesterday, the shares fell 4.3%, which took the trading range below the 3-day low of $58.57 on volume of 14.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MRK: 53.43 (-1.30)
IPO Calendar: Biotech Companies Lead List Of 7 IPOs
at Investor's Business Daily - Mon Oct 13, 3:33PM CDT
In a big year for biotech IPOs, four more are scheduled to debut this week, including the year's largest -- Forward Pharma. Seven initial public offerings in total are expected this week, looking to raise a combined $1.7 billion. Forward Pharma (FWP)...
DM: 28.40 (+2.27), BIIB: 302.74 (-2.95), FWP: 19.00 (+1.50), KITE: 32.56 (+0.71), XENE: (), MRK: 53.43 (-1.30), CFG: 21.80 (-0.05), ZAYO: (), ATRA: 10.65 (+0.54), TEVA: 51.56 (+1.47), VBAY: (), GWB: 18.00 (unch)